Veraxa Biotech proposes raising conditional capital ceiling to CHF 459,789 via bylaw change

• Veraxa Biotech set a July 24, 2026 extraordinary shareholder vote on bylaw changes expanding its equity issuance flexibility.
• Proposed Article 3a amendment would raise conditional capital for Shareholder Options 1 to CHF 459,789.06 via up to 52,071,110 new registered shares.
• Subscription rights would be excluded for that conditional capital, enabling issuance tied to equity-linked financing instruments or warrants.
• Proposed Article 3d amendment would lift the capital band, authorizing issuance of up to 70,703,906 shares through Dec. 31, 2030.
• Proposed Article 15 amendment would expand the board size cap to seven members.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-007294), on July 06, 2026, and is solely responsible for the information contained therein.